

Improved Protection Against Cervical Cancer

PreTect[®] SEE

Supports Cytology to increase women`s safety!

Be confident!

Focus on the infection that matters!

HPV mRNA E6/E7
16, 18, 45



Clinical benefits of using PreTect SEE


- Qualitative detection of E6/E7 mRNA expression from HPV 16, 18, 45
- Intrinsic sample control ensuring sample adequacy
- High clinical specificity minimizing unnecessary interventions
- High PPV for CIN2+
- Enhances identification of cervical adenocarcinoma
- Low positivity rate in general population
- CE-IVD kit



PreTect[®] SEE

Background

- Cervical cancer is caused by the continuous over-expression of the E6/E7 oncogenes from the high-risk HPV virus¹⁾
- 10-30% of women below 40 years of age have an HPV-infection;²⁾ But the majority of these infections are harmless and will clear spontaneously³⁾
- HPV 16, 18 and 45 are aggressive types associated with a rapid development and causes > 90% of all cervical cancer worldwide in young women⁴⁾
- Despite well-established screening programs, the incidence of cervical cancer increases in young women^{5),6)}
- 50% of women diagnosed having severe pre-stages are below 35 years of age⁷⁾
- Cervical adenocarcinomas, clearly linked to HPV 16, 18, 45, have increased in its prevalence over the last decades^{5),8)}



References

- 1) Zur Hausen H (2002) *Nat Rev Cancer* 2(5):342-350. Review
- 2) Preisler S et al (2013) *PLOS ONE* 8(3):e59765
- 3) Elfgrén et al (2000) *Am J Obstet Gynecol* 183(3):561-567
- 4) Munoz N et al (2004) *Int J Cancer* 111(2):278-285
- 5) www.kreftegiestet.no/globalassets/publikasjoner-og-rapporter/livmorhalskreft/arsrapport/arsrapport-livmorhalsprogrammet-2015.pdf
- 6) NORDCAN; Cancer stat fact sheets; Norway-Cervix uteri: <http://www-dep.iarc.fr/NORDCAN/english/StatsFact.asp?cancer=212&country=578>
- 7) Tjalma W et al (2013) *Int J Cancer* 132(4):854-867
- 8) Van der Horst J et al (2017) *Cancer Med* 6(2):416-423

Test Information	
Individual HPV genotyping	E6/E7 mRNA HPV 16, 18 and 45
Intrinsic Sample Control (ISC):	Targeting mRNA from housekeeping gene
Sample type:	Cervical samples
Preservatives:	PreTect TM (PreTect AS) PreservCyt/ThinPrep (Hologic) SurePath (BD Diagnostics)
Input-material:	Isolated Nucleic Acid (DNA/RNA)*
Technology:	Real time NASBA Isothermal amplification (41°C) Four specific molecular beacons
Format:	96-well PCR plate Pre-filled with reagents n=94
Assay time:	~ 150 minutes
Instrumentation:	Fluorescence reader / RT-PCR (CFX-96/QuantStudio5)

* DNA/RNA isolation reagents not included.

Key Facts

- PreTect SEE is a qualitative CE-IVD kit identifying women having carcinogenic expression of high-risk HPV types that may induce cervical cancer
- Co-testing with PreTect SEE and Cytology will improve the existing screening program sensitivity without an excessive follow-up workload
- High clinical specificity; Low positive rate in the general population
- Ideal as stand-alone test in low-income countries
- High capacity and low cost

DNA	mRNA
Double stranded	Single stranded
Storing genetic info	Decoding DNA info to proteins
Indicates presence of virus	Indicates gene activity

For further information please contact us!

PreTect AS

Industriveien 8 | N-3490 Klokkearstua | Norway
Tel.: +47 32 79 88 00 | www.pretect.no
E-mail: pretect@pretect.no

